Literature DB >> 22809251

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Jinhyun Kim1, Alexander J Lazar, Michael A Davies, Jade Homsi, Nicholas E Papadopoulos, Wen-Jen Hwu, Agop Y Bedikian, Scott E Woodman, Sapna P Patel, Patrick Hwu, Kevin B Kim.   

Abstract

BACKGROUND: Spindle cell melanoma represents a rare but distinct subset of melanoma, and its genomic spectrum has not been fully defined.
METHODS: We searched our institutional database for patients with a diagnosis of pure spindle cell-type melanoma whose tumors had been analyzed for BRAF, NRAS, and KIT mutations using pyrosequencing technique.
RESULTS: We identified 24 patients with spindle cell melanoma, including 10 patients with desmoplastic melanoma, whose tumors had been analyzed for at least one of the three genes. The median Breslow thickness was 2.6 mm, and the most common site of the primary melanoma was the trunk, followed by the head and neck region. BRAF, NRAS and KIT genomic sequencing was performed successfully in 20, 18 and 14 patients, respectively. Among the 20 melanomas with completed BRAF-sequencing analysis, 6 (30%) harbored a mutation, of which 5 (83%) had a V600E mutation and 1 (17%) had a V600R mutation. None of the melanomas harbored NRAS or KIT mutations.
CONCLUSION: As has been reported in other common types of melanoma, V600 BRAF mutation is the most common mutation of those tested in spindle cell melanoma. NRAS or KIT mutation appears to be rare, if not completely absent.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809251      PMCID: PMC3881367          DOI: 10.1111/j.1600-0560.2012.01950.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  22 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

3.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

4.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

5.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

6.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

7.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Authors:  J-H Lee; J-W Choi; Y-S Kim
Journal:  Br J Dermatol       Date:  2011-03-21       Impact factor: 9.302

8.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

9.  Malignant melanoma in black American and white American populations. A comparative review.

Authors:  D S Reintgen; K M McCarty; E Cox; H F Seigler
Journal:  JAMA       Date:  1982-10-15       Impact factor: 56.272

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  6 in total

Review 1.  GISTogram: a graphic presentation of the growing GIST complexity.

Authors:  Riccardo Ricci; Angelo Paolo Dei Tos; Guido Rindi
Journal:  Virchows Arch       Date:  2013-08-23       Impact factor: 4.064

2.  Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.

Authors:  Stephan W Jahn; Karl Kashofer; Iris Halbwedl; Gerlinde Winter; Laila El-Shabrawi-Caelen; Thomas Mentzel; Gerald Hoefler; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2015-03-13       Impact factor: 7.842

Review 3.  Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.

Authors:  Roy Rabbie; Peter Ferguson; Christian Molina-Aguilar; David J Adams; Carla D Robles-Espinoza
Journal:  J Pathol       Date:  2019-02-15       Impact factor: 7.996

4.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Authors:  A Hunter Shain; Maria Garrido; Thomas Botton; Eric Talevich; Iwei Yeh; J Zachary Sanborn; Jongsuk Chung; Nicholas J Wang; Hojabr Kakavand; Graham J Mann; John F Thompson; Thomas Wiesner; Ritu Roy; Adam B Olshen; Alexander Gagnon; Joe W Gray; Nam Huh; Joe S Hur; Klaus J Busam; Richard A Scolyer; Raymond J Cho; Rajmohan Murali; Boris C Bastian
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

5.  Spindle cell melanoma: Incidence and survival, 1973-2017.

Authors:  Zhe Xu; Ping Shi; Feiluore Yibulayin; Lei Feng; Hao Zhang; Alimujiang Wushou
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

6.  Evolution of superficial spreading melanoma to resemble desmoplastic melanoma: case report.

Authors:  Martin G Cook; Barry W E M Powell; Megan E Grant; Adele C Green
Journal:  Virchows Arch       Date:  2021-07-20       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.